Nivetha Ganesan

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder et al. · Journal of Clinical Oncology · 2021 · 199 citations · Full text

Medicine, Oncology, Pharmacology +13

Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants

Peter G. Cordeiro, Paola Ghione, Qunying Hu et al. · Journal of Plastic Reconstructive & Aesthetic Surgery · 2020 · 184 citations · Full text

Medicine, Oncology, Surgery +15

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen et al. · Blood · 2021 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

Paola Ghione, Promie Faruque, Neha Mehta–Shah et al. · Blood Advances · 2020 · 96 citations · Full text

Medicine, Oncology, Pathology +12

Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer

Anjana Bhardwaj, Harpreet Singh, Kimal Rajapakshe et al. · Oncotarget · 2017 · 88 citations · Full text

Medicine, Molecular Biology, Oncology +13